title: Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
abstract: The increasing number of longer-living patients with diffuse large B-cell lymphoma (DLBCL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with DLBCL from 2004 to 2010. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-year interval. Detailed data on treatment were extracted from the Population-based HAematological Registry for Observational Studies. Two hundred fifty-six patients responded (84 %, T1). Compared to patients treated with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone every 21 days ((R-)CHOP21), those who underwent (R-)CHOP14 more often reported tingling in the hands and feet (27 vs 42 %, p = 0.02) and fatigue (35 vs 46 %, p = 0.03) and reported a lower global health status/HRQoL. Mean HRQoL was statistically and clinically relevantly lower among DLBCL patients compared to a normative population (p < 0.01). Persistent tingling in hands/feet was reported more often by older patients and patients treated with (R-)CHOP14 independently of the other characteristics. Furthermore, patients who reported symptoms exhibited significantly lower HRQoL compared to patients without symptoms/worries. Patients treated with (R-)CHOP14 reported more neuropathic symptoms, more fatigue, and a lower HRQoL than patients treated with (R-)CHOP21. Alertness for persistent symptoms that occur during and after treatment of DLBCL patients is needed and may help to avoid lasting negative influence on their HRQoL.
authors.affiliation: Comprehensive Cancer Centre the Netherlands, Research Department, Eindhoven Cancer Registry, P.O. Box 231, 5600 AE, Eindhoven, The Netherlands, s.oerlemans@iknl.nl.
authors.forename: Simone
authors.initials: S
authors.lastname: Oerlemans
authors.forename: Djamila E
authors.initials: DE
authors.lastname: Issa
authors.forename: Esther C
authors.initials: EC
authors.lastname: van den Broek
authors.forename: Marten R
authors.initials: MR
authors.lastname: Nijziel
authors.forename: Jan Willem W
authors.initials: JW
authors.lastname: Coebergh
authors.forename: Peter C
authors.initials: PC
authors.lastname: Huijgens
authors.forename: Floortje
authors.initials: F
authors.lastname: Mols
authors.forename: Lonneke V
authors.initials: LV
authors.lastname: van de Poll-Franse
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000453:epidemiology / Q000209:etiology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005221:Fatigue / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D009437:Neuralgia / Q000139:chemically induced / Q000453:epidemiology; D010292:Paresthesia / Q000139:chemically induced / Q000453:epidemiology; D017060:Patient Satisfaction; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D012042:Registries; D000069283:Rituximab; D011795:Surveys and Questionnaires; D017741:Survivors / Q000523:psychology*; D063189:Symptom Assessment; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone